Impact BioMedical/$IBO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Impact BioMedical
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
- Ticker
- $IBO
- Sector
- Health
- Primary listing
- AMEX
- Employees
- 2
- Headquarters
- Houston, United States
- Website
- www.impactbiomedinc.com
IBO Metrics
BasicAdvanced
$37M
24.45
$0.18
-
-
Price and volume
Market cap
$37M
52-week high
$7.11
52-week low
$2.43
Average daily volume
16K
Financial strength
Current ratio
0.043
Quick ratio
0.009
Profitability
EBITDA (TTM)
-4.225
Gross margin (TTM)
-1,031.58%
Net profit margin (TTM)
4,247.37%
Operating margin (TTM)
-12,621.05%
Effective tax rate (TTM)
265.16%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-17.31%
Return on equity (TTM)
71.22%
Valuation
Price to earnings (TTM)
24.45
Price to revenue (TTM)
926.325
Price to book
3.63
Price to tangible book (TTM)
-6.1
Price to free cash flow (TTM)
303.437
Free cash flow yield (TTM)
0.33%
Free cash flow per share (TTM)
0.014
Growth
Revenue change (TTM)
52.00%
Earnings per share change (TTM)
-100.38%
3-year earnings per share growth (CAGR)
-46.63%
IBO Financial Performance
Revenues and expenses
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.